The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...

The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

AstraZeneca (AZN) stock in focus as the U.S. FDA expands approval for its lymphoma therapy Calquence with chemoimmunotherapy ...

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

Current health news highlights include debates over Medicare pricing for drugs like Ozempic and Wegovy, management shifts ...

AstraZeneca Pharma India rose 1.10% to Rs 10,754 after the firm received approval from the Central Drugs Standard Control Organisation (CDSCO) to import pharmaceutical formulations of eculizumab ...

Eculizumab, a monoclonal antibody, is indicated for the treatment of two rare and life-threatening conditions: Paroxysmal ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.